Finding Immune Nascent Type 1 Diabetes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: phone call, email/mail.
- Who it may be relevant to
- Registry conditions: Healthy Adult, Type 1 Diabetes (T1D). Basic parameters: 1 year — 99 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Finding Immune Nascent Type 1 Diabetes (FIND T1D)
Overview
The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. The main question it aims to answer is: What form of recruitment communication is most effective for completing a type 1diabetes home screening kit? Researchers will compare two types of recruitment contact: email and mail based communication (low-touch) versus phone contact and follow-up by a research team member (high-touch). Participants will be contacted either via email/mail or by phone and asked if they want to complete a type 1 diabetes home screening kit.
Interventions
- Behavioral phone call
Recruitment through phone call - Behavioral email/mail
Recruitment through email and mail
Primary outcome measures
- Rates of Returned Home Screening Kits [Time frame: From enrollment to the end of study at 3 years.]
- Rates of Consent [Time frame: From enrollment to the end of study at 3 years.]
Secondary outcome measures (1)
- Percent of Kits with Adequate Blood Volume [Time frame: From enrollment to the end of study at 3 years.]
Eligibility criteria
Inclusion criteria
- Participant must be in Indiana Biobank
- Participant must be able to provide consent
- Ages 1-99 including pregnant women
Exclusion criteria
- Refusal to sign informed consent for home screening is exclusionary for the home screening portion of the study
- While other medical conditions are allowable prior diabetes diagnosis is exclusionary for home autoantibody screening
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Screening
Study locations
United States · 1 center
- Indiana University School of Medicine — Indianapolis
Identifiers
NCT: NCT07663136 · 31119